Abstract
Chronic pain is extremely difficult to treat. Current traditional treatments may be limited with regard to analgesic efficacy or side effects. Gene therapy for the management of pain is a band-new therapy strategy. Neurotropic herpes simplex virus type I (HSV-I) -based vector is suitable for gene transfer treatment of nervous system diseases. This review is focused on the application of HSV-I-based vector and its expressing proenkephalin in treatment of inflammatory pain, neuropathic pain and cancer pain. Key words: herpes simplex virus; vector; pain; gene therapy; enkephalin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Anesthesiology and Resuscitation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
